Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dart Therapeutics: Backed By Non-Profits, Open To Venture

This article was originally published in Start Up

Executive Summary

Dart Therapeutics is owned and funded by rare disease patient foundations, and tiny ones at that. But with its first candidate, for Duchenne muscular dystrophy, it has created a special ownership structure to move the program forward. That takes a page from the recent private investor playbook, and Dart’s CEO wants to use venture capital to fund more programs without losing its patient-centric vision and grassroots passion.

You may also be interested in...



Duchenne Muscular Dystrophy: Pipeline And Partnering Snapshot

A full pipeline of symptomatic and disease-modifying treatments for Duchenne will transform a long dormant orphan market into a hotly contested commercial prize. But some issues, foremost the scarcity of trial patients, threaten to stall progress in the field.

Partnering Door Opens For Sarepta With 48-Week Data In Hand

Sarepta Therapeutics’ positive data on its lead muscular dystrophy drug eteplirsen puts the company in a strong position at the partnering table and sets the stage for a neck and neck race with GSK/Prosensa to bring the first treatment for the rare disease to market.

Series A Financing For Annovation Includes Potential Buyout By TMC

The newest company created under the Atlas Venture Development Corp. model, Annovation, will develop a next-generation anesthetic through proof-of-concept, with investor The Medicines Co. holding an option to acquire the new company.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC092370

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel